<DOC>
	<DOCNO>NCT02644616</DOCNO>
	<brief_summary>The investigator research early improvement fluid retention mid-term prognosis administration tolvaptan patient tricuspid regurgitation right heart failure leave heart valve replacement .</brief_summary>
	<brief_title>The Safety Efficacy Tolvaptan Patients With Tricuspid Regurgitation Right Heart Failure After Left Heart Valves Replacement</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>1 . Patient tricuspid regurgitation right heart failure leave heart valve replacement 2 . Patients take exist diuretic 3 . The patient willing participate study 1 . Patients hypersensitivity study drug 2 . Anuric patient 3 . Patients hypernatremia 4 . Female patient pregnant , possibly pregnant , lactate , plan become pregnant 5 . Malignant tumor 6 . Patients serious hepatic disorder Serious Renal failure 7 . Patients otherwise judge investigator subinvestigator inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>tolvaptan</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>left heart valve replacement</keyword>
</DOC>